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1 |  BACKGROUND
Iran (Persia; officially the Islamic Republic of Iran), is the 
18th most populous country (with over 81 million indi-
viduals) in the world (www.amar.org.ir). Iran is located in 
Western Asia with 1,648,195 km2 land, as the second largest 
country in the Middle East and the 17th in the world. Iran 
is bordered to the north by the Caspian Sea, to the south by 
the Persian Gulf and the Gulf of Oman, to the northwest by 
Turkey and Armenia and the Republic of Azerbaijan, to the 
west by Iraq, to the northeast by Turkmenistan, and to the east 
by Afghanistan and Pakistan. Tehran is the country's capital, 
its largest and the leading economic and cultural city.
Iran is the origin of the world's oldest civilizations 
(Barrington, 2012; Whatley, 2001) since Elamite kingdoms 
in the fourth millennium BCE to Iranian Medes in the sev-
enth century BCE when it was first unified (Encyclopædia 
Britannica, 2010); as the largest empires in history from 
Eastern Europe to the Indus Valley (Achaemenid) was founded 
in Persia in the sixth century BCE by Cyrus the Great (Sacks, 
Murray, & Brody, 2005). Greater Iran used to refer to the re-
gions with Iranian culture including the Caucasus, and parts 
of West, South, and Central Asia (https://en.wikipedia.org/
wiki/Greater_Iran) (Figure 1). This extensive Iranian culture 
in other regions could be due to a long life contact with the 
various imperial dynasties of Iran, whereas North Caucasus 
was not under straight Iranian rule. It also could be either due 
to being part of Persian Empire (e.g., Medes, Achaemenids, 
Parthians, Sassanians, Samanids, Safavids, Afsharids, and the 
Qajars) for a long historical period of time; or happened by 
so many peoples who promote and respect their cultures (e.g., 
Bahrain, Tajikistan, and the western parts of South Asia).
In the fourth century BCE, it fell to Alexander the Great 
leading to division into some Hellenistic states. An Iranian 
disobedience developed to the Parthian Empire followed 
(in the third century CE) by the Sasanian Empire as a lead-
ing world power till the seventh century CE when Arab 
Muslims conquered it and displaced the Zoroastrianism and 
Manichaeism with Islam (Jeffreys & Haarer, 2006; Stillman, 
1979).
Iran made major contributions with so much impact on 
art, science, and medicine for some centuries, including 
Avicenna in the 10th century who authored The Canon of 
Medicine (Al‐Qanun fi't‐Tibb). The Canon of Medicine was a 
five‐volume medical encyclopedia used as the reference med-
ical textbook in Europe up to the 18th century (McGinnis, 
2010). Then Iran was conquered by the Mongols and the 
Turks till an Iranian state and nationality reestablished in the 
15th century (Curtis & Stewart, 2005). In the 18th century, 
Iran was one of the most powerful countries; however, a se-
ries of conflicts with the north neighbor Russian Empire led 
to significant territorial losses in the 19th century (Dowling, 
2014; Fisher et al., 1991), followed by the 1953 coup and 
1979 revolution.
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Interestingly, prior and consistent with what has been 
currently proved and accepted as a fact, Persian historically 
believed in the equal contribution of women and men in for-
mation of a child and its hereditary characteristics since the 
prophet Zoroaster (~1,700 years BC) who expressed equal 
right for both sexes to choose how to live life. To store the 
egg (gametes) from reproductive organs (gonads) for future 
conception was also mentioned in Vandidad book (by Mades 
in the Median dynasty; 800–700 BC). Also 800 years ago, 
“the Great Iranian Poet” Ferdowsi of 10th century explains 
an equal contribution of man and woman in the transmis-
sion of characters and fetus formation; it is mentioned in 
Shahnameh—the world's longest epic poem created by a 
single poet, and the national epic of Greater Iran (Browne, 
1998). Regarding an Iranian prince—Keykhosrow‐, Ferdowsi 
versified “this handsome child has got the royal characteris-
tics of two kingdoms: from Afrasiab (the king of Turan) and 
Keykavus (the emperor of Iran)” (Abolqasem, 2007), respec-
tively, his maternal and paternal grandfathers. This is directly 
addressing to both sides’ lines of descent and the traits in-
heritance from ancestors, whereas the maternal ancestor is 
mentioned prior to the paternal one (Figure 2) (Kariminejad 
& Khorshidian, 2012). However, world scientists did not be-
lieve in reproduction (but believed in ovism and other hypoth-
eses) till renaissance happened. In the recent 2–3 centuries 
tremendous efforts have been made in the field of reproduc-
tion biology including the embryo formation via ovum and 
spermatozoa union (fertilization).
From population demography viewpoint, Iran is a big re-
gional multicultural country consisting of numerous ethnic 
and linguistic groups, including Persians (61%; including 
Gilaks and Mazandaranis 4% each), Azeris (16%), Kurds 
(10%), Lurs (6%), Balochs (2%), Arabs (2%), Turkmens 
(1%), Talyshs (1%), Qashqais (1%) (The World Factbook – 
Iran, ). Iran population from religious point of view, 99.39% 
are Muslims including Shia (90%–95%), Sunni (4%–8%), and 
other Islamic subgroups (2%) (Figure 3a–b) (https://en.wiki-
pedia.org/wiki/Ethnicities_in_Iran).
The female and male median age of the Iranian popula-
tion is 31.3 and 30.9 years (totally 31.1 years), respectively, 
with 75.1% living in urban areas. The biggest metropolitan 
areas are the cities of Tehran (13.26 million), Mashad (3.37 
million), Isfahan (2.24 million), Shiraz (1.87 million), Karaj 
(1.85 million), and Tabriz (1.77 million).
Consanguineous marriages are allowed in Iran, and are 
common in most ethnic groups, communities, and reli-
gions of Iranians including Azeris, Kurds, Lurs, Balochs, 
Arabs, Turkmens, Gilaks, Talyshs, Qasqais, and Mazanis. 
Consanguineous marriage is not only common but also has 
a positive trend in Iranian community. In a survey in Persian 
population of Iran, the consanguinity status (rate) for 1,789 
marriages showed 8.8% in the generation with marriages 
before 1949 versus 19% after 1979 (Akrami, Montazeri, 
Shomali, Heshmat, & Larijani, 2009). Moreover in the recent 
years, the consanguineous marriage rate has been reported as 
high as 38.6% with the highest among first cousins (27.9%) 
(Saadat, Ansari‐Lari, & Farhud, 2004).
According to the reports by the Ministry of Health and 
Medical Education (MHME) in Iran, the mean maternal and 
paternal ages are 28 and 33 years, respectively; and the total 
fertility rate is 2.01 children born/woman. The current birth 
and growth rates are, respectively, 10.6 births per 1,000 in-
habitants and 1.24. Changes in socioeconomic status (SES) 
may contribute to the increasing parental age and low fertil-
ity rates. Higher education levels of women and their more 
exposure to the workforce vacancies from one way, and 
F I G U R E  1  Greater Iran in terms 
of ethnicity from historic point of view 
(By Hosseiniran ‐ paint, CC0, https://
commons.wikimedia.org/w/index.
php?curxml:id=42801778)
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gender inequality, the consequences of sanctions and eco-
nomic hardship from another way, play an important role 
in above‐mentioned facts and rates. All these resulted in a 
significant increase in the age of marriage and maternal age 
above 35 years old, which may have a direct increasing effect 
on congenital and genetic defect in subsequent generations 
(Heidari & Dastgiri, 2014). Also there is an active process 
of immigration from Iran which have a considerable impact 
on the ethnic diversity via genetic drift and shuffling mainly 
because of different SES. There is a trend of improvement 
in pregnancy care (i.e., routine folic acid supplementation), 
and increase in the general healthcare of the population. Also 
based on the religious permission (Fatwa) and because of 
prenatal screenings and public education, there is a signif-
icant increase in the voluntary termination of pregnancies 
upon the detection of fetal abnormalities. The frequency of 
congenital disorders is notably high (38.3/1,000) in Iran, in-
cluding congenital malformations (17.9/1,000), single gene 
disorders (16.4/1,000 with G6PDd), chromosomal disorders 
(3.1/1,000), and congenital infections (0.9/1,000) (http://
ghdx.healthdata.org/organizations/ministry-health-and-med-
ical-education-iran). The greatest prevalence and propor-
tion rates belonged to musculoskeletal disorders, skin, and 
urogenital anomalies, and may be different in different eth-
nicities due to higher consanguineous marriages, different 
genetic makeup and SES (Vatankhah, Jalilvand, Sarkhosh, 
Azarmi, & Mohseni, 2017). A mild decrease has been de-
tected just in the frequency of anencephaly and spina bifida 
since 1990s when folate was added as a routine supplement 
for the women in reproductive age prior to pregnancy and in 
the first trimester, in Iran.
2 |  METHODS
2.1 | Legal, social, and ethical implications 
of genetic testing in Iran
The Office of Study for Humanistic and Islamic Science 
on Medicine and Medical Ethics at the MHME started its 
activity in 2001 and has drafted the 27‐clause act entitled, 
“The Protection Code for Human Subjects in Medical 
Research” (Iranian National Commission for UNESCO, 
2001). The most important ethical issues included: in-
formed consent, human rights during research, certifying 
research projects according to risks and benefits, privacy 
of information, paying compensation for harm imposed by 
research on human subjects, cultural and religious implica-
tions of research, rights of prisoners, and individuals with 
mental retardation and of psychotic patients, and research 
on the fetus. The Act has been customized according to the 
Code of Religious Laws and cultural issues peculiar to the 
Iranian population. Then, MHME required all universities 
and biomedical research centers to develop bioethics com-
mittees based on a uniform guideline which was prepared 
by the Office of the Deputy for Research, MHME. The 
parliament of the (Islamic Republic of) Iran approved an 
act on abortion in 2005, and under this law, a pregnancy 
could be terminated within the first 4 months of pregnancy 
(18 weeks by LMP), if the fetus was mentally or physically 
handicapped, or where the mother's life was likely to be in 
danger; as long as three specialists confirmed the problem 
(IR Iran Parliament, 2005).
2.2 | Prenatal diagnosis and therapeutic 
termination of pregnancy
Prenatal diagnosis (PND) is an acceptable practice in Iran. 
There are two main legal grounds for PND in Iran; the main 
one is the endangerment of a mother's life, and the other 
one is parents’ severe hardship. The “hard to treat diseases” 
include chromosomal disorders, major hemoglobinopathies, 
inborn errors of metabolism, Duchene muscular dystrophy, 
F I G U R E  2  Flowchart showing Keykhosrow's inheritance 
of characteristics from both parents’ (mother and father) fathers 
(Keykavous & Afrasiab) (by Kariminejad MH & Khorshidian A. 
Indian J Hum Genet. 2012)
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and spinal muscular dystrophy which are all diagnosed early 
in embryonic period that medical abortion is possible and 
advisable in Iran The Iranian law, based on religious au-
thorities (fatwa), allows for termination of pregnancy before 
the 19th week of embryo (the 120th day of the pregnancy 
by LMP) on the affected fetus with a severe disease in ul-
trasonography imaging and/or by a detected disease‐caus-
ing mutation/chromosomal aberration including fetuses with 
Down syndrome. Most of the population of Iran are religious/
traditional so the interruptions of pregnancy were relatively 
rare. However, fatwa has put forth in the recent years, that 
“any” fetal disease may be terminated if it puts the parents 
in hardship (Kosaryan & Rabiei, 2014). Preimplantation ge-
netic diagnosis (PGD) is provided in private or semi‐private 
sectors in very limited centers. PGD is recommended mainly 
by the obstetricians and gynecologists (OB/G) specialists 
for couples at risk for the chromosomal aberrations and very 
well‐known disease‐causing mutations.
Despite this, extensive changes in the healthcare system 
including ethical changes are still necessary to overcome the 
ethical obstacles including knowledge gap and informed con-
sent, privacy and confidentiality and availability of health-
care services. The approaches to genetic testing are limited 
but diverse in Iranian, mainly because of the differences in 
the traditions of different ethnicities. The multi‐ethnic Iranian 
communities (composed of more than 10 ethnic groups) are 
homogeneous, and include about 50% of Iranian population.
2.3 | The genetic law in Iran?
The purpose of the law is to provide the screening tests, ge-
netic testing, and genetic counseling for early detection of 
some targeted genetic diseases to all, including women in re-
productive ages, and pregnant women. It is defined in section 
75 of the 6th National Development Plan (2016) (https://she-
nasname.ir/1391-09-30-20-01-30/tosee/plan6/3579.html), 
the Ministry of Health and Medical education (MHME) is 
in charge to recruit cooperative and private sectors to pro-
vide accredited genetic laboratories to the couples who are 
in need. Also MHME and State Welfare Organization of Iran 
(http://en.behzisti.ir/Portal/Home/) need to provide the ac-
cess to genetic counseling to them. There is a possibility to 
perform genetic tests outside the country if necessary.
2.4 | Medical/Human genetic professionals 
in Iran
As mentioned above, despite all other residency programs in 
different disciplines, medical genetics has not been yet a medi-
cal specialty recognized by MHME and the Iranian Medical 
Council (IRIMC) (http://irimc.org/). However, MHME de-
fined the curriculum and professional criteria for Ph.D. in med-
ical genetics in five universities, with the annual acceptance of 
15 holders of a master degree (in human genetics, biomedi-
cal sciences, and midwifery). The Ph.D. in medical genetics 
program includes 24‐month syllabus of cytogenetics, mo-
lecular, biochemical, and medical/clinical genetics followed 
by a comprehensive exam. After passing the comprehensive 
exam, doing a dissertation and oral (defense) examination is 
necessary prior to taking the medical genetic national board 
examination. The board‐certified Ph.D. medical geneticists are 
recognized as laboratory specialties in the health system by 
MHME and IRIMC. There is no separate training program for 
cytogenetics, molecular, and biochemical genetics specialties. 
A Ph.D. medical geneticist can serve as director of a genetics 
laboratory, and sign out the results of tests in the fields of cy-
togenetics, molecular, and biochemical genetics.
Also a fellowship in molecular pathology after completion 
of pathology residency program in an approved pathology de-
partment is available for pathologists. There is an accredited 
2‐year Master degree training program in human genetics in 
16 Iranian universities; 82 students have been accepted in the 
M.Sc. human genetics in the current academic year. One with 
the M.Sc. in human genetics can serve as a genetics laboratory 
manager; and every genetics laboratory requires to have at 
least a manager with Master degree in human genetics. There 
is no particular training program for the genetic counseling.
2.5 | Budgeting of genetic services in Iran
The total budget of Iran's healthcare system is 5.95 Billion 
USD, which represents 6.9% of the GDP, whereas 4% 
comes from private resources. Although the overall health 
expenditure index has been raised 71 times during the 
past 20 years, it is still very low per capita in Iran with, 
respectively, 47.8% and 41.2% out‐ of‐ pocket and public 
health expenditure (Khosravi, Soltani, Javan‐Noughabi, & 
Faramarzi, 2017). Iranian government (MHME) funds 42% 
of the budget, and support the major burden in the public 
funding of healthcare.
Genetic tests for screened cases or the ones whom recom-
mended by a physician because of suspicions of any chromo-
somal aberration, thalassemia, and/or PKU are covered by 
insurances. Also the health insurances mostly cover the costs 
of molecular genetic tests as long as their indications are 
well‐defined (because of being well‐known disease‐causing 
mutations) and they are carried out in Iran. Two examples for 
indicated well‐defined mutations could be p.508del mutation 
in CFTR (cystic fibrosis), and 35delG in conexin26 (deaf-
ness). Meanwhile, the tests are mostly affordable for people 
in need in above‐mentioned cases. The costs of IVF and the 
genetic services which are necessary because of infertility 
are also covered by the national health insurance. Otherwise, 
many genetic tests are not covered by health insurances and 
therefore are hardly affordable for most of the families in 
need.
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2.6 | Clinical genetic laboratories
By now, there are 49 clinical genetic (diagnostic) labo-
ratories in different provinces of Iran; including 13 in 
Tehran (Tehran), 5 in Fars (Shiraz), 4 in Isfahan (Isfahan), 
2 in Azarbayejan (Tabriz), 4 in Khorasan (Mashad), 4 in 
Khoozestan (Ahvaz), 1 in Balochestan (Zahedan), 3 in 
Kerman (Kerman), 1 in Kermanshah (Kermanshah), 3 in 
Gilan (Rasht), 4 in Mazandaran (3 in Sari & 1 in Babol), 2 in 
Hormozgan (Bandarabbas), 1 in Hamedan (Hamedan), 1 in 
Kurdestan (Sanandaj), and 1 in Alborz (Karaj). About half 
of them are in charge of the national screening program for 
assigned genetic disorders (thalassemia, PKU, etc).
Almost all genetic laboratories in Iran have both the cyto-
genetic and molecular genetics divisions; the set‐up of each 
genetic laboratory is individual and different from others. 
The directors of both cytogenetics and molecular genetics 
divisions are Ph.D. in medical genetics. S/he could be di-
rector of both simultaneously. The cytogenetics laboratories 
provide two types of services: clinical diagnosis and PND. 
However, the cytogenetics laboratories are independent and 
found outside of the genetic departments in hospitals, as there 
is no such clinical department/unit due to the lack of medical 
genetics program as a clinical discipline.
All the genetics laboratories are regulated by the MHME. 
There are just three active laboratories offering Chromosomal 
microarray analysis (CMA) for clinical and PND in Tehran. 
Perhaps there are three more laboratories which offer CMA 
in three big cities (Isfahan, Ahvaz, and Shiraz) which are 
mainly for PGD and PND. Cytogenetic tests of oncology/
hematology are also performed in the genetics laboratories 
or in the oncology/hematology departments (Bone Marrow 
Transplantation in a hospital affiliated with Tehran University 
of Medical Sciences, TUMS). Generally, the genetic tests for 
diseases which are specific to a hospital and/or department 
(e.g., ophthalmology, endocrinology, oncology/hematology, 
etc) are set up in a very limited number of genetic laborato-
ries within the hospitals.
The number of genetic laboratories which are licensed 
and regulated by the MHME are growing rapidly in the recent 
years. However, there are (for maximum) just 4–5 big and 
mother private genetic laboratories in capital Tehran provid-
ing cytogenetics and molecular genetic testing.
The performance of next‐generation sequencing 
(NGS) was literally announced in 2016 in Iran. However, 
the samples for different diagnostic panels (WES and 
GWAS) are still shipped outside the country, rather than 
being performed as a clinical service in any of the Iranian 
accredited laboratories. In turn, it is due to lack of the 
NGS platforms hardware maintenance and support (by 
the main company providers) for the analysis of genetic 
variation secondary to Iranian Transactions and Sanctions 
Regulations (ITSR).
3 |  RESULTS
3.1 | The Iranian national genetic database 
(Iranome)—integrating research and clinical 
genetics
Iran with its very diverse population in terms of ethnicity, 
is among the most underrepresented populations in currently 
available human genomic variation databases; this is impor-
tant because many genomic variations are ethnicity‐specific.
Similar to the “100,000 Genomes Project” funded by the 
Department of Health of the United Kingdom (http://www.
genomicsengland.co.uk), the Iranian MHME with its part-
ner—Genetics Research Center (GRC) at the University of 
Social Welfare & Rehabilitation Sciences, Tehran, Iran and 
Dalla Lana School of Public Health at University of Toronto, 
Toronto, Ontario, Canada—have recently (2017) decided 
to launch the Iranome database (available at www.iranome.
com). It has been launched by performing whole‐exome se-
quencing on 800 individuals from eight major ethnic groups 
in Iran. The groups included 100 healthy individuals from 
each of the following ethnic groups: Arabs, Azeris, Balochs, 
Kurds, Lurs, Persians, Persian Gulf Islanders, and Turkmen. 
They represent over 80 million Iranians, and perhaps over 
half a billion populations in Middle East with a rapid popula-
tion growth expectations for the future (MENA Policy Brief, 
2001) Despite the shortages in clinical genetic services in 
Iran, there is a significant increase in the number and quality 
of publications in this field in the past two decades.
3.2 | Genetic services in Iran
3.2.1 | Genetics and genetic counseling 
in the hospitals and community
No work was reported on genetics in Iran until 1936 when 
a genetic course was added to the curriculum of biology in 
the universities. The Iranian Genetics Society was founded 
in 1966. The first‐genetic counseling clinic opened, and the 
first department of Human Genetics and Anthropology was 
founded in 1972 at the School of Public Health, University 
of Tehran by DD Farhud. In 1986, he reported some genetic 
information on the Persian population including higher rates 
of chromosomal, external genital, and thorax and abdominal 
anomalies, and other syndromes; similar rates of cleft lip 
and palate, joint dislocation, and finger anomalies in Iranian 
infants compared to other populations were found (Akbari, 
Papiha, Roberts, & Farhud, 1986; Farhud, Walizadeh, & 
Kamali, 1986). The first diagnostic (cyto)‐genetic laboratory 
was established in 1979 by MH Kariminejad (http://www.
irangenepath.com/).
Although medical genetics have been practiced by a num-
ber of physicians and/or scientists for several years in Iran, 
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there is still no medical genetics and clinical genetics resi-
dency and fellowship program accredited by MHME.
Now, the departments of medical genetics have been es-
tablished in several medical schools. However, medical ge-
netic services in Iran are not well‐organized in a uniform, 
comprehensive, and academic discipline mainly due to the 
lack of residency program in medical and clinical genetics. 
There is no accredited degree for genetic counseling too. 
Some of the units are offering genetic services in indepen-
dent units with different sizes in some university hospitals. 
The services which are offered in these units/departments 
mainly include genetic counseling, cytogenetic services 
with the ability of prenatal diagnosis for the common chro-
mosomal aberrations, and a very limited number of molec-
ular genetic tests (beta‐thalassemia, panel of thrombophilia, 
etc). The above‐mentioned genetic services and tests in the 
medical genetics laboratories of the university hospitals 
are offered to the public and covered by the medical insur-
ances. In all these university hospital medical genetic lab-
oratories, there is at least one PhD (or rarely MD/PhD) in 
medical genetics graduated from a foreign university (and 
qualified after the review and evaluation by the Iranian board 
of medical genetics as PhD in Human/Medical Genetics). 
Otherwise, they should have graduated from a PhD program 
in Medical Genetics from a local university (within Iran). 
There are just 2–3 MHME‐accredited programs of PhD in 
Medical Genetics. The genetic counseling is mainly done by 
the physicians who participated in the short courses or work-
shops certified by MHME.
3.3 | The national program for the 
detection and the prevention of birth defects
There are two recently established comprehensive centers for 
genetic counseling services in Iran; the second was launched 
with an academic affiliation in Tehran in 2016 (https://finan-
cialtribune.com/articles/people/50834/tehran-s-first-genetic-
center-launched). The first one was established by the Shiraz 
University of Medical Sciences. The genetic counseling ser-
vices include maternal and pediatric medicine and laborato-
ries of molecular genetics, cytogenetic, and prebirth tests.
Genetic counseling in the area of infertility and abortion 
has been more highlighted in Iran, and is well established in 
some special centers which were founded for this specific pur-
pose. Now, there are 2–8 such centers in the capitals/big cities 
in each province of Iran. The most prominent ones in Tehran 
(capital) are the infertility clinics at Royan and Avicenna 
Research Institutes which function as semi‐private and accept 
the national health insurances. Royan Institute (http://www.
royaninstitute.org/)—a leader of stem cell research and also 
one of the most advanced clinics for infertility treatment in 
Iran—was established in 1991 as a public nonprofitable orga-
nization affiliated to Academic Center for Education, Culture 
and Research for Reproductive Biomedicine and infertility 
treatments. Then it this institute was approved by MHME as 
a cell‐based research center in 1998.
In Tehran, there are some other private clinics of infertil-
ity and abortion which are mainly affiliated with the OB/G 
hospitals or departments. A reason of this progress in terms 
of quantity and quality of the genetic services in the area of 
infertility and reproduction could be the government spe-
cial policies on population growth. Most of these clinics 
and laboratories are doing PND and PGD (each is part of 
the IVF division and genetic department) offering molecular 
and cytogenetic diagnosis mainly for the cases of infertility, 
recurrent abortion, chromosomal aberration, and sex selec-
tion. Prenatal clinics are found in most of them; though a big 
highly specific center—Hope Generation—for the prenatal 
clinic including genetics and metabolic genetics exists in 
Tehran. However, cancer genetics clinics rarely exist; perhaps 
mainly in MAHAK (https://iscc-charity.org/mahak-charity/) 
for the malignancies in children.
The last but not the least, most of genetic laboratories 
in the community are private, although are run by a faculty 
member of the genetic department. Their main focuses are 
on the most common monogenic diseases diagnosed via 
the Sanger sequencing technology, MLPA, Real‐time PCR, 
RFLP, and FISH.
Premarriage screening and genetic testing has been re-
cently proposed (by scientific and academic Iranian societies 
since 2016) to be mandatory for all couples in Iran but not 
approved yet. Upon its approval by the parliament of Iran, 
the establishment of the genetics comprehensive centers is 
essential. The mandatory tests include first and second tri-
mester combined screening (Down syndrome, trisomy 13, 
18, plasma protein‐A, HCG, and nuchal translucency via ul-
trasound). Although premarital genetic tests are now manda-
tory, these limited number of genetic centers may not meet 
the needs and coverage of the millions of people. There is 
certainly a real need to expand genetic services in the public 
health sector in Iran. Financial constraint is currently a seri-
ous obstacle for the health sector as well as for the people. 
On the other hand, Iran still needs the required technologies 
for some genetic tests; so the samples have to be sent to other 
countries for standard lab testing.
Screening of congenital hypothyroidism and thalassemia 
has been successfully performed across the country by the 
MHME. Apart from thalassemia, a national pilot newborn 
screening program for other congenital and some frequent ge-
netic diseases/disorders (listed in Table 1) has also been ini-
tiated by Iranian health authorities since late 2017. Subjects 
for the screening of the targeted genetic diseases/disorders 
(including breast and colon cancers) are the families/individ-
uals with a pattern of heredity.
The high cost of genetic services at secondary and ter-
tiary levels does not allow many people to get access to 
8 of 12 |   BEHNAM ANd ZAKERI
these services despite their needs. Governments will there-
fore need to allocate necessary resources to make the es-
sential genetic services available for everyone needing these 
in the community. By considering all shortages in human 
and financial resources, it is not possible to launch highly 
special genetic counseling centers in all provinces promptly. 
However, a 5‐year goal is to set up at least 8–9 such com-
prehensive genetic centers at prominent medical universi-
ties like Isfahan, Tabriz, Mashhad, and Ahvaz, and refer 
samples from across the country to these laboratories and 
centers.
3.4 | Lagging in Genetic Services in Iran
Iran obviously lags behind many developed countries in ge-
netic services, and more diagnostic laboratories are required 
to make up for such shortcomings. A data network linking all 
state and private labs is underway in Iran to prevent repetitive 
and unneeded genetic tests.
Another measure under preparation is clinical guidebooks 
for development of genetic services and to set the standards 
for the services. A significant number of samples are sent 
abroad for genetic diagnostic tests, in a controversial man-
ner between the physicians, patients, MHME, and insurance 
companies. The Health Reform Plan launched in May 2014 
resulted in the establishment of 800 specialized and super-
specialty clinics by 2017; 17,000 doctors and specialists are 
working in these clinics, 10,000 of whom are full‐time staff 
in the public health sector. However, there is an argument and 
criticism for no planning of the medical genetics residency 
programs and disciplines in health education, as well as ge-
netic services, by MHME in the past 3–4 decades.
3.5 | Current status of genetic diseases 
in Iran
There is no survey to measure the frequencies and rates of 
various genetic diseases in the Iranian population and/or in 
different ethnic subgroups of it. However, based on a few 
small cohort studies of autosomal recessive and some X‐
linked ones, a relatively high‐frequency rate might be pos-
sibly found in a single community due to a unique founder 
mutation. Also in some diseases, the same mutations might be 
found in several communities either since they were ancient 
mutations or exchanged by the marriages between them. Lots 
of (rare) autosomal recessive genetic disease are predicted 
to be more frequent in Iranian population versus European 
and American populations. This might be due to high rate 
of consanguinity, and close/common origin with Caucasians 
(as some Caucasian countries were) separated from Iran by 
Russian Empire in the 19th century.
In the past decades, some reports have been published 
on ethnic‐specific differential pattern and frequencies of 
T A B L E  1  National NBS program for congenital and genetic 
diseases/disorders in Iran
Approved national NBS 
Program
Pilot national NBS Program 
(launched since late 2017)
Thalassemia Down syndrome
Phenylketonuria (PKU) Hemophilia A—Hemophilia B





 Duchenne & Becker muscular 
dystrophies
 Mental Retardation































 Amino acid metabolism 
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mutations in several rare Mendelian diseases in the Iranian 
population and ethnic groups:
1. Iranian Jews in Israel had a high frequency of inbreeding 
with very unique and ancient Jewish community and a 
novel genotype in blood markers (Cohen, Simhai, 
Steinberg, & Levene, 1981).
2. A particular high frequency of MSI‐H has been reported 
in sporadic colorectal cancer in Iran (Moghbeli et al., 
2011).
3. The relative quantification (RQ) in normal individuals 
were within the carrier range of 0.31–0.57 for SMN1 (in 
SMA), estimating a carrier frequency of 5% in the Iranian 
population. It is higher than in the European population 
(Hasanzad et al., 2010).
4. A high prevalence (39.3%) of subjects (respectively, 
24.3% homozygous T/T CYP2D6*10 and 15% heterozy-
gous C/T CYP2D6*10 as poor and intermediate metabo-
lizers) among Iranians; therefore, the harmful effects of 
drugs are relatively common (Bagheri et al., 2015).
5. An ABCD1 mutation (c.253dup leading to 
p.Arg85Profs*110) was identified in 35 affected individu-
als (out of 96 pedigree members) among an expanded 
pedigree among Lurs. Therefore, the prevalence of X‐
ALD is expected to be higher among consanguineous Lurs 
ethnicity (Mehrpour et al., 2016).
6. )MSH3, MSH6, APC, and PIK3CA genes are predicted to 
play a bigger role in the pathogenesis of colon cancer in 
Iranian population (Ashktorab et al., 2017).
7. In a pilot study of Persian nephropathic cystinosis popula-
tion, the common 57‐kb deletion was not observed; how-
ever, at least 50% of mutations were observed in exons 6 
and 7 of CTNS (Ghazi et al., 2017).
8. In another pilot study, the role of kidney anion exchanger 
1 gene (AE1) mutations is highlighted in Iranian children 
with distal renal tubular acidosis (dRTA); moreover a 
novel mutation pattern of AE) has been reported in pa-
tients with distal renal tubular acidosis in Iran (Hooman 
et al., 2015).
9. Among all Iranian patients with cystic fibrosis, just 16.6% 
has shown a delta F508 mutation in CFTR (either ho-
mozygote or heterozygote) (Najafi et al., 2015), which is 
different from many other populations around the world.
Some of the common genetic disorders which are known 
as more frequent ones among Iranians include thalassemia, 
G6PD deficiency, SMA, cystic fibrosis (CF), Familial 
Mediterranean Fever (FMF), phenylketonuria (PKU), and 
maple syrup urine disease (MSUD). FMF caused by muta-
tions in the MEFV gene has been already reported with a very 
high prevalence in Middle East Arab, Turkish, Jewish, and 
Armenian populations. In the recent years, a high 27.4%–
25.5% average frequency rate of MEFV mutation carriers 
have been reported among healthy Iranian Azeri Turkish and 
overall Iranian populations (Bonyadi et al., 2009) Meanwhile, 
MEFV mutations are generally frequent in healthy Iranian in-
dividuals across different ethnic groups with the highest rates 
among Balochs, Gilaks, and Azeri Turkish (Beheshtian et al., 
2016) Therefore, an extra screening program for carrier de-
tection in different ethnic groups of Iranians has been highly 
suggested.
T A B L E  2  The first 25 (monogenic) clinical entities with a higher 
referral rate in Iran (Based on the author's referral genetics laboratory 
at the university hospital)
1 B‐thalassemia HBH
2 Thrombophilia MTHFR, PAI1
3 Familial Mediterranean Fever 
(FMF)
MEFV
4 Phenylketunuria (PKU) PAH
5 Cystic Fibrosis (CF) CFTR
6 Maple Syrup Urine Disease 
(MSUD)
BCKDHA‐B, DBT
7 Spinal Muscular Atrophy 
(SMA)
SMN1
8 Fragile X Syndrome FMR1
9 Condenital Adrenial 
Hyperplasia (CAH) (21‐OH 
Def.)
CYP21A2
10 Primary Hyperoxaluria I AGXT1, GRHPR, 
HOGA1
11 Cystinosis CTNS







15 Distal RTA SLC4A1, 
ATP6V1B1 
ATP6V0A4
16 Bartter's Syndrome SLC12A3, ROMK, 
CLCNK
17 Citrillunemia ASS1




20 Epidermolysis Bullosa  
21 Alport Syndrome Col4A
22 GM1 GLB1
23 Ichthyosis  
24 Thyrosinemia I FAH
25 Galactosemia GALT
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The genetic diseases with a higher referral rate to the au-
thor's genetics laboratory at a university hospital in Iran are 
listed in Table 2.
Congenital defects registries have been recently imple-
mented in Iran; thus there is still no big cohort study for the 
rates and numbers of Mendelian disorders. However, there 
is an estimate of significantly higher frequencies for autoso-
mal recessive disorders due to high rate of consanguinity and 
intraethnic marriages, and close ethnicity with Caucasians 
in north, northwest, and northeast of Iran (Afzal, Lund, & 
Skovby, 2018; Keyfi et al., 2018).
Traditionally, a world esophageal cancer belt –with the 
same or close ethnicity—has been recognized which ex-
tends from western/northern China through Mongolia, and 
the southern part of the former Soviet Union (Kazakhstan, 
Turkmenistan, Uzbekistan, Tajikistan), Iran, Iraq, and east-
ern Turkey (Reed & Johnston, 1993). In this regard, a suc-
cessful 5‐year survey (2004–2008) was performed (as part 
of GEMINI and Golestan Cohort Study) by the Digestive 
Disease Research Center (DDRC) of Tehran University of 
Medical Sciences in collaboration with IARC and the US 
National Cancer Institute (NCI, NIH). In this study, 50,000 
cases were registered in Golestan province which is located 
in a high‐risk region for esophageal cancer in northern Iran 
(Pourshams et al., 2010). However, no gene or genetic marker 
has been yet identified for esophageal cancer in this big 
cohort.
The Rare Diseases Foundation of Iran (RADOIR) (with an 
affiliation to “Rare Diseases Patients without Borders”) was 
established in 2008 to create a patient registry and to help indi-
viduals with rate genetic diseases in Iran (http://radoir.com/).
4 |  CONCLUDING REMARKS
Attention has been focused on the field of genetics and 
genomics in Iran in recent years and some efforts have been 
enforced and implemented. However, they are totally not 
adequate, considering the advances in medical genetics and 
genomics in the past two decades around the world.
Premarital genetic testing in consanguineous and/or in-
traethnical marriages is highly recommended in Iran and the 
communities with such population demographics.
Overall, considering the lack of medical genetics resi-
dency programs in the Iranian health education system, big 
demand due to high consanguinity and intraethnic marriages, 
and the mandatory program of the 5‐year economic develop-
ment plan, there is a lag in genetic services and necessity to 
an immediate response to fill this big gap in Iran. Further pro-
grams of population carrier detection and prenatal testing for 
most of monogenic diseases should be implemented because 
of the high rate of carriers in Iranian population.
The role which NGS technologies play in practicing 
medical/clinical genetics, disease diagnosis and thus patient 
management, is prominent and significant. It can also be 
cost‐effective for a National Health System. However, NGS 
and the highest quality services in genetics and genomic 
medicine have not been practically implemented at the clin-
ical level in Iran yet. This pitfall is multifactorial including 
underestimating the medical/clinical genetics discipline as a 
clinical residency program by MHME and IRIMC, the re-
cent economic decline in addition to the international and 
US sanctions against Iran, and some defects in national reg-
ulations and administrations. Although as clarified in the 
National constitution fundamental law and re‐emphasized 
in the 6th National Development Plan, the Iranian govern-
ment authority is in charge of providing the standard level 
of health including genetic services to all Iranian individu-
als who are in need. The Office of Foreign Assets Control 
(OFAC) authorizes the exportation or reexportation to Iran 
of all items meeting the definition of the term “medical de-
vice” [section 560.530(e)(3) of the ITSR] (https://www.
treasury.gov/resource-center/faqs/Sanctions/Pages/faq_iran.
aspx#lic_agmed_amend). This includes the NGS equip-
ment and tools; however, the sanctions have a significant 
negative impact on it indirectly. A considerable part of the 
delay and lagging in genetic services in Iran, in particular 
in the recent two decades, has been due to the conflict of 
interests. Although it was due to the shortage in qualified 
professional human resources in the field of clinical diag-
nostic genetic laboratories, a number of the private genetic 
laboratory directors had been the members of the Iranian 
Board of Medical Genetics at MHME, while simultaneously 
serving as advisor/counselor to MHME policy maker(s) in 
the field of genetics. Synchronously, some of them had also 
been the members of a team who approved the permission 
and licenses of other private genetic laboratories, and also in 
charge of reviewing the complaint files against a laboratory 
geneticist colleague (as referees). All above‐mentioned pa-
rameters and factors resulted in a delay and restriction/con-
striction in the expansion of services in genetics and genomic 
medicine in Iran, despite a highly consanguineous popula-
tion, and despite the big efforts which have been done by a 
number of medical laboratory geneticists.
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